https://www.aigom.it/wp-content/uploads/2024/07/loc28.10.png796570Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-22 09:17:592024-07-22 09:17:59AIGOM CONGRESSO NAZIONALE-CARCINOMA DEL POLMONE: QUALI NOVITA’ NEL 2024? V EDIZIONE 28 OTTOBRE 2024-VERONA
https://www.aigom.it/wp-content/uploads/2024/07/ART23.7.png1256960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-22 08:42:442024-07-22 08:54:30ADJUVANT TRASTUZUMAB EMTANSINE VERSUS PACLITAXEL PLUS TRASTUZUMAB FOR STAGE I HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BREAST CANCER: 5-YEAR RESULTS AND CORRELATIVE ANALYSES FROM ATEMPT
https://www.aigom.it/wp-content/uploads/2024/07/ART16.7.LOC_.png1272960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-15 07:09:222024-07-15 07:09:22CAPItello-291 STUDY GROUP. CAPIVASERTIB IN HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2024/07/AIG.LOC_.png403700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-09 10:04:092024-07-10 07:55:36LINEE DI INDIRIZZO SULL’INTEGRAZIONE OSPEDALE-TERRITORIO IN ONCOLOGIA DI AGENAS-MINISTRO DELLA SALUTE 1 LUGLIO 2024
https://www.aigom.it/wp-content/uploads/2024/07/aigom11.10-e1720512898846.png800569Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-09 08:15:212024-07-15 07:19:10CARCINOMA METASTATICO:QUALI NOVITA’? 11 OTTOBRE 2024 ROMA
https://www.aigom.it/wp-content/uploads/2024/07/ART09.07.png1172960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-09 07:46:032024-07-09 07:55:25OVERALL SURVIVAL IN PATIENTS WITH ENDOMETRIAL CANCER TREATED WITH DOSTARLIMAB PLUS CARBOPLATIN-PACLITAXEL IN THE RANDOMIZED ENGOT-EN6/GOG-3031/RUBY TRIAL.
https://www.aigom.it/wp-content/uploads/2024/07/ART.02.07.png1211960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-01 07:11:442024-07-01 07:35:08LORLATINIB VERSUS CRIZOTINIB IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER: 5-YEAR OUTCOMES FROM THE PHASE III CROWN STUDY
https://www.aigom.it/wp-content/uploads/2024/06/ART.25.6.png1205950Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-24 07:06:202024-06-24 07:06:20OSIMERTINIB AFTER CHEMORADIOTHERAPY IN STAGE III EGFR-MUTATED NSCLC.
https://www.aigom.it/wp-content/uploads/2024/06/ART18.6.png1080935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-18 09:01:252024-06-18 09:01:25IMPROVED CLINICAL STAGING SYSTEM FOR LOCALIZED PANCREATIC CANCER USING THE ABC FACTORS: A TAPS CONSORTIUM STUDY
